Akash Tewari
Stock Analyst at Jefferies
(4.75)
# 613
Out of 4,382 analysts
475
Total ratings
57.7%
Success rate
13.7%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintained: Buy | $35 | $26.04 | +34.41% | 42 | Jun 1, 2026 | |
| BNTX BioNTech SE | Maintained: Buy | $138 | $88.08 | +56.68% | 37 | Jun 1, 2026 | |
| JBIO Jade Biosciences | Maintained: Buy | $16 → $40 | $16.94 | +136.13% | 2 | Jun 1, 2026 | |
| LLY Eli Lilly and Company | Maintained: Buy | $1,300 → $1,330 | $1,131.42 | +17.55% | 42 | May 22, 2026 | |
| GILD Gilead Sciences | Maintained: Buy | $180 | $129.16 | +39.36% | 2 | May 22, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintained: Buy | $113 → $104 | $56.77 | +83.20% | 36 | May 21, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Buy | n/a | $729.53 | - | 3 | May 8, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $85 → $95 | $73.65 | +28.99% | 3 | May 6, 2026 | |
| CCCC C4 Therapeutics | Maintained: Buy | $14 | $3.85 | +263.64% | 1 | Apr 30, 2026 | |
| NBIX Neurocrine Biosciences | Maintained: Buy | $174 → $172 | $163.88 | +4.95% | 26 | Apr 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $96 → $113 | $74.48 | +51.72% | 7 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $885 → $890 | $635.45 | +40.06% | 35 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $350 | $349.58 | +0.12% | 2 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $282 → $580 | $446.83 | +29.80% | 2 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $980 → $1,008 | $891.32 | +13.09% | 42 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $58 | $42.80 | +35.51% | 26 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 → $46 | $52.70 | -12.71% | 19 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $26 → $35 | $18.00 | +94.44% | 2 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 → $42 | $24.04 | +74.71% | 6 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $18 → $20 | $11.26 | +77.62% | 8 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $80 | $71.48 | +11.92% | 19 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $398 → $502 | $486.98 | +3.08% | 16 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $86 → $96 | $86.92 | +10.45% | 4 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $138 | $120.79 | +14.25% | 34 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $52 → $10 | $7.42 | n/a | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $70 → $68 | $57.27 | n/a | 13 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $183 | $238.57 | n/a | 18 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 → $2.5 | $3.66 | n/a | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 → $17 | $13.52 | n/a | 7 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $17 | $1.43 | n/a | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $15.88 | n/a | 2 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $7.49 | n/a | 2 | Jan 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $9 | $34.19 | n/a | 1 | Jul 19, 2019 |
Pfizer
Jun 1, 2026
Maintained: Buy
Price Target: $35
Current: $26.04
Upside: +34.41%
BioNTech SE
Jun 1, 2026
Maintained: Buy
Price Target: $138
Current: $88.08
Upside: +56.68%
Jade Biosciences
Jun 1, 2026
Maintained: Buy
Price Target: $16 → $40
Current: $16.94
Upside: +136.13%
Eli Lilly and Company
May 22, 2026
Maintained: Buy
Price Target: $1,300 → $1,330
Current: $1,131.42
Upside: +17.55%
Gilead Sciences
May 22, 2026
Maintained: Buy
Price Target: $180
Current: $129.16
Upside: +39.36%
BioMarin Pharmaceutical
May 21, 2026
Maintained: Buy
Price Target: $113 → $104
Current: $56.77
Upside: +83.20%
argenx SE
May 8, 2026
Maintained: Buy
Price Target: n/a
Current: $729.53
Upside: -
Spyre Therapeutics
May 6, 2026
Maintained: Buy
Price Target: $85 → $95
Current: $73.65
Upside: +28.99%
C4 Therapeutics
Apr 30, 2026
Maintained: Buy
Price Target: $14
Current: $3.85
Upside: +263.64%
Neurocrine Biosciences
Apr 7, 2026
Maintained: Buy
Price Target: $174 → $172
Current: $163.88
Upside: +4.95%
Mar 26, 2026
Maintained: Buy
Price Target: $96 → $113
Current: $74.48
Upside: +51.72%
Mar 11, 2026
Maintained: Buy
Price Target: $885 → $890
Current: $635.45
Upside: +40.06%
Mar 10, 2026
Initiated Coverage: Hold
Price Target: $350
Current: $349.58
Upside: +0.12%
Mar 10, 2026
Initiated Coverage: Buy
Price Target: $282 → $580
Current: $446.83
Upside: +29.80%
Feb 19, 2026
Maintained: Buy
Price Target: $980 → $1,008
Current: $891.32
Upside: +13.09%
Feb 10, 2026
Maintained: Buy
Price Target: $58
Current: $42.80
Upside: +35.51%
Dec 11, 2025
Maintained: Buy
Price Target: $50 → $46
Current: $52.70
Upside: -12.71%
Dec 5, 2025
Maintained: Buy
Price Target: $26 → $35
Current: $18.00
Upside: +94.44%
Nov 17, 2025
Maintained: Buy
Price Target: $13 → $42
Current: $24.04
Upside: +74.71%
Oct 1, 2025
Upgraded: Buy
Price Target: $18 → $20
Current: $11.26
Upside: +77.62%
Sep 3, 2025
Reiterated: Buy
Price Target: $70 → $80
Current: $71.48
Upside: +11.92%
Aug 12, 2025
Maintained: Buy
Price Target: $398 → $502
Current: $486.98
Upside: +3.08%
Jul 8, 2025
Maintained: Buy
Price Target: $86 → $96
Current: $86.92
Upside: +10.45%
Jun 18, 2025
Maintained: Buy
Price Target: $138
Current: $120.79
Upside: +14.25%
May 2, 2025
Downgraded: Hold
Price Target: $52 → $10
Current: $7.42
Upside: n/a
Apr 23, 2025
Maintained: Buy
Price Target: $70 → $68
Current: $57.27
Upside: n/a
Apr 1, 2025
Maintained: Buy
Price Target: $183
Current: $238.57
Upside: n/a
Jan 29, 2025
Maintained: Hold
Price Target: $6 → $2.5
Current: $3.66
Upside: n/a
Dec 11, 2024
Rated: Buy
Price Target: $16 → $17
Current: $13.52
Upside: n/a
Dec 12, 2022
Initiated Coverage: Buy
Price Target: $17
Current: $1.43
Upside: n/a
Feb 26, 2021
Downgraded: Hold
Price Target: n/a
Current: $15.88
Upside: n/a
Jan 29, 2020
Downgraded: Hold
Price Target: n/a
Current: $7.49
Upside: n/a
Jul 19, 2019
Initiated Coverage: Hold
Price Target: $9
Current: $34.19
Upside: n/a